Zydus Lifesciences Limited has announced its consolidated financial results for the quarter and year ending March 31, 2026.
The company reported a significant increase in total income and net profit, reflecting a strong performance in the final quarter of the fiscal year.
In the March 2026 quarter, Zydus Lifesciences' total income rose by 16.8% year-on-year (YoY) to ₹7,721.20 crore, compared to ₹6,608.50 crore in the same period last year.
Sequentially, the income increased by 10.7% from ₹6,975.90 crore in the December 2025 quarter.
The net profit for the March 2026 quarter saw an 8.7% YoY increase, reaching ₹1,272.50 crore, up from ₹1,170.90 crore a year earlier.
This also marked a 22.1% quarter-on-quarter (QoQ) rise from ₹1,042.10 crore in the December 2025 quarter.
For the full fiscal year 2026, Zydus Lifesciences reported a total income of ₹27,657.90 crore, reflecting a 17.6% YoY growth from ₹23,511.00 crore in the previous year.
The net profit for FY26 increased by 11.4% YoY to ₹5,040.00 crore, compared to ₹4,525.50 crore in FY25.
Read More: Gland Pharma Share Price Gains Over 14% After Q4 FY26 Earnings Results: Net Profit up 96.6% YoY!
The Board of Directors has recommended a final dividend of ₹1 per equity share, which is equivalent to 100% of the face value of each share.
This proposal is subject to the approval of the shareholders at the upcoming Annual General Meeting scheduled for August 11, 2026.
As of May 19, 2026, at 2:30 PM, Zydus Lifesciences share price on NSE was trading at ₹1,042.20 up by 5.16% from the previous closing price.
Zydus Lifesciences has demonstrated robust financial growth in both quarterly and annual terms for FY26. The company's substantial increase in income and net profit underscores its strong market position and operational efficiency.
Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: May 19, 2026, 3:33 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
